Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;26 Suppl 2(Suppl 2):e26107.
doi: 10.1002/jia2.26107.

Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition

Lara Lorenzetti  1 , Nhi Dinh  1 , Ariane van der Straten  2   3 , Virginia Fonner  1 , Kathleen Ridgeway  1 , Michelle Rodolph  4 , Robin Schaefer  4 , Heather-Marie A Schmidt  4   5 , Rachel Baggaley  4
Affiliations

Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition

Lara Lorenzetti et al. J Int AIDS Soc. 2023 Jul.

Abstract

Introduction: Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting injectable cabotegravir (CAB-LA) as PrEP. In considering CAB-LA as an additional PrEP modality for people at substantial risk of HIV, it is important to understand community response to injectable PrEP. We conducted a systematic review of values, preferences and perceptions of acceptability for injectable PrEP to inform global guidance.

Methods: We searched nine databases and conference websites for peer-reviewed and grey literature (January 2010-September 2021). There were no restrictions on location. A two-stage review process assessed references against eligibility criteria. Data from included studies were organized by constructs from the Theoretical Framework of Acceptability.

Results: We included 62 unique references. Most studies were observational, cross-sectional and qualitative. Over half of the studies were conducted in North America. Men who have sex with men were the most researched group. Most studies (57/62) examined injectable PrEP, including hypothetical injectables (55/57) or placebo products (2/57). Six studies examined CAB-LA specifically. There was overall interest in and often a preference for injectable PrEP, though there was variation within and across groups and regions. Many stakeholders indicated that injectable PrEP could help address adherence challenges associated with daily or on-demand dosing for oral PrEP and may be a better lifestyle fit for individuals seeking privacy, discretion and infrequent dosing. End-users reported concerns, including fear of needles, injection site pain and body location, logistical challenges and waning or incomplete protection.

Discussion: Despite an overall preference for injectable PrEP, heterogeneity across groups and regions highlights the importance of enabling end-users to choose a PrEP modality that supports effective use. Like other products, preference for injectable PrEP may change over time and end-users may switch between prevention options. There will be a greater understanding of enacted preference as more end-users are offered anti-retroviral (ARV)-containing injectables. Future research should focus on equitable implementation, including real-time decision-making and how trained healthcare providers can support choice.

Conclusions: Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle.

Keywords: PrEP; acceptability; injectable PrEP; long-acting injectable cabotegravir; pre-exposure prophylaxis; values and preferences.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA diagram.
See this image and copyright information in PMC

References

    1. World Health Organization . HIV data and statistics. World Health Organization; 2020.
    1. World Health Organization . Guideline on when to start antiretroviral therapy and on pre‐exposure prophylaxis for HIV. Switzerland: World Health Organization; 2015. - PubMed
    1. HIV/AIDS JUNPo . Danger: UNAIDS Global AIDS Update 2022. 2022.
    1. Castel AD, Magnus M, Greenberg AE. Pre‐exposure prophylaxis for human immunodeficiency virus: the past, present, and future. Infect Dis Clin North Am. 2014;28(4):563–83. - PubMed
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. - PMC - PubMed

Publication types